ME Therapeutics extends option to license NRC CD22 nanobody CAR asset to Feb. 10, 2027

Bitget2026/10/09 22:35

ME Therapeutics extended its option agreement to license NRC’s nanobody-based CD22 binder for use in CAR therapy. Exercise deadline moved to Feb. 10, 2027. CD22 nanobody remains slated for development within the company’s in vivo CAR program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ME Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009047275) on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

BUZZ - Morningstar maintains fair value estimate for Aurora Australiana due to strong performance in its canning business

路透社•2026/10/15 22:26

BUZZ - Citi remains cautious about the revival of ARB, while Morningstar is optimistic about its value

路透社•2026/10/15 22:21

Updated version 3 - KFC selects Coca-Cola as its soda supplier in the United States, ending its long-term partnership with Pepsi.

路透社•2026/10/15 22:06

Exclusive report - According to sources, chip startup Bolt Graphics is seeking to raise $100 million at a valuation of approximately $700 million.

路透社•2026/10/15 21:31